NCT03445858View on ClinicalTrials.gov

Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

February 12, 2018

Primary Completion Date

November 7, 2023

Study Completion Date

November 7, 2023

Conditions
Childhood Solid TumorChildhood LymphomaRelapsed CancerRefractory CancerAdult Solid TumorAdult Lymphoma
Interventions
DRUG

Pembrolizumab

Patients will receive pembrolizumab every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.

DRUG

Decitabine

Patients will receive decitabine every 28 days.One cycle lasts 28 days. Cycles may repeat for a total of 26 cycles if patient meets criteria to continue protocol therapy.

RADIATION

Hypofractionated Index Site Radiation

Patients will receive a single 3 day course of fixed-dose hypofractionated radiotherapy to one or more index lesions during the first cycle only.

Trial Locations (1)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

All Listed Sponsors
lead

Children's Hospital Medical Center, Cincinnati

OTHER

NCT03445858 - Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young Adults | Biotech Hunter | Biotech Hunter